A Ruthenium(II) Complex Inhibits BRD4 for Synergistic Seno‐ and Chemo‐Immunotherapy in Cisplatin‐Resistant Tumor Cells
Angewandte Chemie International Edition · 2025
DOI: 10.1002/anie.202505689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2025. Verfasst von Jinrong Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Basic Re…. Hauptthemen laut MEDLINE: Ruthenium, Drug Resistance, Neoplasm, Cell Cycle Proteins, Transcription Factors. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: National Science Foundation of China, Natural Science Foundation of Guangdong Province for Distinguished Young Scholars, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Drug resistance is a significant challenge for tumor therapy. Activating immunity is an effective method to combat drug‐resistant tumors. Utilizing metallic chemotherapeutic agents to induce nonapoptotic programmed cell death is a practical approach to stimulate immunity. Besides, triggering tumor cell senescence, named senotherapy, is also an effective but often ignored method to induce immune responses. Despite some progress, reports on metallic immunotherapeutic stimuli are sparse and mainly delve into the level of organelle targeting, with vague drug–target mechanisms. Here, we report a Ru(II) complex ( Ru2c ) inhibits BRD4 with high affinity at a nanomolar constant. After encapsulation into biotin‐DNA cage, Ru2c@biotin‐DNA cage was demonstrated to kill drug‐resistant cancer cells through a synergistic apoptosis‐ferroptosis‐senescence pathway, exhibiting 51‐fold anticancer activity compared to the commercial inhibitor JQ‐1. Ru2c effectively erased drug‐resistant tumors and activated innate and acquired immunity in vivo. To the best of our knowledge, Ru2c is the first metal‐based BRD4 inhibitor to achieve synergistic seno‐immunotherapy and chemo‐immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Basic Research Center of Excellence for Functional Molecular Engineering, Scho…
- MOE Key Laboratory of Theoretical Organic Chemistry and Functional Molecule, School of Chemistry and Chemical Engineering, Hunan University of Science and Technology, Xiangtan, 400201, P.R. China.
Förderung
- National Science Foundation of China
- Natural Science Foundation of Guangdong Province for Distinguished Young Scholars
- Natural Science Foundation of Guangdong Province
- Science and Technology Innovation Program of Hunan Province of China
- National Natural Science Foundation of China
Zitieren
APA
Yang, J., Wang, F., Huang, S., Feng, T., Xiong, K., Chen, Y., & Chao, H. (2025). A Ruthenium(II) Complex Inhibits BRD4 for Synergistic Seno‐ and Chemo‐Immunotherapy in Cisplatin‐Resistant Tumor Cells. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202505689
Vancouver
Yang J, Wang F, Huang S, Feng T, Xiong K, Chen Y, et al. A Ruthenium(II) Complex Inhibits BRD4 for Synergistic Seno‐ and Chemo‐Immunotherapy in Cisplatin‐Resistant Tumor Cells. Angewandte Chemie International Edition. 2025. doi:10.1002/anie.202505689
BibTeX
@article{Yang2025,
author = {Yang, Jinrong and Wang, Fa and Huang, Shuqi and Feng, Tao and Xiong, Kai and Chen, Yu and Chao, Hui},
title = {A Ruthenium(II) Complex Inhibits BRD4 for Synergistic Seno‐ and Chemo‐Immunotherapy in Cisplatin‐Resistant Tumor Cells},
journal = {Angewandte Chemie International Edition},
year = {2025},
doi = {10.1002/anie.202505689}
}
EUVIMED